Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments Centre

Multiple sclerosis

Click on the title for more information (where available).

Lord, J., Onyimadu, O., Harris, P., Shepherd, J., Frampton, G. Ocrelizumab for treating relapsing multiple sclerosis: A Single Technology Appraisal. Southampton Health Technology Assessments Centre (SHTAC), 2018.

Cooper, K, Bryant J, Harris P, Loveman E, Jones J, Welch K. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: A Single Technology Appraisal. SHTAC, 2013.

Bryant J, Clegg AJ, Milne R. A systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence of effectiveness and cost? Journal of Neurology, Neurosurgery and Psychiatry 2001;70:574-9.                                                                                                                                                      
Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opinion on Pharmacotherapy 2001;2(4):623-39.  

Milne R, Clegg A, Bryant J. Multiple sclerosis: review unsystematic (letter). British Medical Journal 2001;322:299.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×